Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALSA: Self-administration of Somatuline Autogel in Acromegaly
NCT00447499Phase 3Completed
- Sponsor
- Ipsen
- Start
- Apr 2007
- Primary completion
- Dec 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanreotide in acromegaly, sponsored by Ipsen. Primary endpoint: Percentage of Subjects or Their Partners That Are Competent to Self-administer Somatuline Autogel at 24 weeks. Started Apr 2007; status: completed.
02
Drugs
lanreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00447499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00447499.